Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

IBUPROFEN AND FAMOTIDINE (FAMOTIDINE; IBUPROFEN) | LOERadar

Viewing data from:

IBUPROFEN AND FAMOTIDINE

ANDA

FAMOTIDINE; IBUPROFEN | A216814 | ASCENT PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Products (1)

#001 — 26.6MG;800MG

AB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Mar 15, 2023

No patent or exclusivity listings for this strength.